GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Revenue

MiNK Therapeutics (MiNK Therapeutics) Revenue : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Revenue?

MiNK Therapeutics's revenue for the three months ended in Mar. 2024 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. MiNK Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


MiNK Therapeutics Revenue Historical Data

The historical data trend for MiNK Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics Revenue Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
0.69 - - - -

MiNK Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MiNK Therapeutics's Revenue

For the Biotechnology subindustry, MiNK Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiNK Therapeutics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's Revenue falls into.



MiNK Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiNK Therapeutics  (NAS:INKT) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


MiNK Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


MiNK Therapeutics (MiNK Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010